All In Biotech

Drug Trial Radar · NCT07472517

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

DAREON ® -Lung-1: A Phase III Multi-center, Open-label, Randomised Trial of Intravenous Obrixtamig in Combination With Atezolizumab, Carboplatin, and Etoposide vs. Atezolizumab, Carboplatin, and Etoposide as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 670 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

670

Planned (sponsor's estimate)

Start

Apr 13, 2026

Primary completion

Sep 9, 2028

Study completion Jul 30, 2029

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Mar 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival when compared to standard treatment alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another purpose of the study is to test a medical device being developed to measure levels of the tumour marker DLL3. Participants are put into 2 groups randomly, which means by chance. One group receives obrixtamig and standard treatment. The other group receives standard treatment without obrixtamig. All treatments are given as infusions into a vein. Participants are in the study for up to 3 years. During this time, they visit the study site regularly. Participants in the group receiving obrixtamig stay overnight at the study site following the first 2 obrixtamig treatments. At the visits, doctors check the size of the tumour(s). The results are compared between the 2 groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Conditions

  • Small Cell Lung Cancer (SCLC)
  • Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Interventions

  • obrixtamigDrug

    obrixtamig

  • atezolizumabDrug

    atezolizumab

  • carboplatinDrug

    carboplatin

  • etoposideDrug

    etoposide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: Up to 36 months

Locations

242 sites in 42 countries. Site status is shown where the registry gives one.

  • Infirmary Cancer Care

    Mobile, Alabama · Not yet recruiting

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Not yet recruiting

  • Bioresearch Partner - Hialeah Hospital

    Hialeah, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Norton Cancer Institute, Downtown

    Louisville, Kentucky · Recruiting

  • Pikeville Medical Center

    Pikeville, Kentucky · Not yet recruiting

  • Epic Medical Research - Monroe

    Monroe, Louisiana · Recruiting

  • Epic Medical Research - Shreveport

    Shreveport, Louisiana · Recruiting

  • University of Maryland School of Medicine

    Baltimore, Maryland · Recruiting

  • Veterans Affairs Ann Arbor Healthcare System

    Ann Arbor, Michigan · Not yet recruiting

  • HCA MidAmerica Division, Inc.

    Kansas City, Missouri · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Cape Fear Valley Cancer Center

    Fayetteville, North Carolina · Recruiting

  • AHN Cancer Institute - Allegheny General

    Pittsburgh, Pennsylvania · Recruiting

  • Baptist Cancer Center - Memphis

    Memphis, Tennessee · Recruiting

  • University of Wisconsin

    Madison, Wisconsin · Not yet recruiting

  • Hospital Britanico de Buenos Aires

    CABA, Argentina · Recruiting

  • Clinica Adventista Belgrano

    CABA, Argentina · Recruiting

  • Clinica Privada Independencia

    Munro, Argentina · Recruiting

  • Sanatorio Allende S.A.

    Nueva Córdoba, Argentina · Recruiting

  • Sanatorio Parque S.A.

    Rosario, Argentina · Recruiting

  • Prince of Wales Hospital-Randwick-66496

    Randwick, New South Wales, Australia · Recruiting

  • Cancer Research South Australia

    Adelaide, South Australia, Australia · Recruiting

  • Ballarat Regional Integrated Cancer Centre

    Ballarat, Victoria, Australia · Recruiting

  • Hospital Elisabethinen Linz

    Linz, Austria · Recruiting

  • Johannes Kepler University Linz

    Linz, Austria · Recruiting

  • Standort Penzing der Klinik Ottakring

    Vienna, Austria · Recruiting

  • Centre Hospitalier Interrégional Edith Cavell (CHIREC)

    Brussels, Belgium · Not yet recruiting

  • Universitair Ziekenhuis Antwerpen

    Edegem, Belgium · Not yet recruiting

  • Universitair Ziekenhuis Brussel

    Jette, Belgium · Not yet recruiting

  • UZ Leuven

    Leuven, Belgium · Not yet recruiting

  • Hospital de Amor

    Barretos, Brazil · Recruiting

  • Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa Sociedade Simples

    Porto Alegre, Brazil · Recruiting

  • Irmandade da Santa Casa de Misericórdia de Porto Alegre

    Porto Alegre - RS, Brazil · Recruiting

  • Fundaçao Faculdade Regional de Medicina de Sao Jose do Rio Preto

    São José do Rio Preto, Brazil · Recruiting

  • Multiprofile Hospital For Active Treatment-Uni Hospital Ltd.

    Panagyurishte, Bulgaria · Not yet recruiting

  • MHAT Heart and brain

    Pleven, Bulgaria · Not yet recruiting

  • Verspeeten Family Cancer Centre (LHSC)

    London, Ontario, Canada · Not yet recruiting

  • Sault Area Hospital

    Sault Ste. Marie, Ontario, Canada · Not yet recruiting

  • Icegclinic

    La Florida, Chile · Recruiting

Showing 40 of 242 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.